Ely Gold Royalties (ELYGF)(ELY:CA) – Poised to Broaden Its Horizon?

Wednesday, September 02, 2020

Ely Gold Royalties (ELYGF)(ELY:CA)

Poised to Broaden Its Horizon?

As of April 24, 2020, Noble Capital Markets research on Ely Gold Royalties is published under ticker symbols (ELYGF and ELY:CA). The price target is in USD and based on ticker symbol ELYGF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. Ely Gold Royalties Inc is an emerging royalty company with producing and development assets focused in Nevada and the Western US. It offers shareholders a low-risk leverage to the current price of gold and low-cost access to long-term gold royalties.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Transactions expected to close soon. We expect Ely to close on several announced transactions this month. First is the acquisition of an additional one percent NSR royalty on Coeur Mining’s Lincoln Hill property announced on July 21. Second is the acquisition of a package of three net smelter returns (NSR) royalties on properties in Nevada announced on August 11.

    Ready to expand its opportunity set?  Ely Gold Royalties has largely focused its efforts on Nevada. However, based on an expanding universe of royalty companies and an increasingly competitive acquisition environment, we would not be surprised if the company expands its opportunity set by considering other mining jurisdictions, including in Latin America. While we would expect gold royalties to …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Leave a Reply